Stage (next event)
Catalyst Info & Data Links
We will not be following this anymore because AIMT was bought by Nestle
May 11, 2020 Aimmune recently completed a positive pre-IND meeting with the U.S Food and Drug Administration(FDA) regarding the Company’s multi-tree nut program, and the Company is preparing the development plan for this new program.
PALISADE Group of Clinical Investigators. (2018). AR101 oral immunotherapy for peanut allergy. New England Journal of Medicine, 379(21), 1991-2001.
Wambre, E., Bajzik, V., DeLong, J. H., O’Brien, K., Nguyen, Q. A., Speake, C., ... & Farrington, M. (2017). A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders. Science translational medicine, 9(401), eaam9171.
HC updated 5/21/20
Mechanism of Action
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post